A Phase IIIb Multicenter, Single-Arm, Open-Label Surveillance Study of Susceptibility to Baloxavir Marboxil in Patients With Influenza
Latest Information Update: 19 Feb 2025
Price :
$35 *
At a glance
- Drugs Baloxavir-marboxil (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Acronyms Pebblestone
- Sponsors Roche
- 14 Nov 2023 Status changed from not yet recruiting to recruiting.
- 26 Oct 2023 New trial record